Get an alert when ABBOTT HEALTHCARE PRODUCTS LTD files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-11-30 (in 6mo)

Last made up 2025-11-16

Watchouts

None on the register

Cash

Latest balance sheet

Net assets

£77M

+24.7% vs 2023

Employees

2

-71.4% vs 2023

Profit before tax

£18M

+27.4% vs 2023

Name history

Renamed 2 times since incorporation

  1. ABBOTT HEALTHCARE PRODUCTS LTD 2010-02-17 → present
  2. SOLVAY HEALTHCARE LIMITED 1995-06-12 → 2010-02-17
  3. DUPHAR LABORATORIES LIMITED 1969-03-05 → 1995-06-12

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £2,291,000£1,221,000
Operating profit £50,000-£139,000
Profit before tax £13,794,000£17,567,000
Net profit £11,969,000£15,345,000
Cash
Total assets less current liabilities £62,062,000£77,407,000
Net assets £62,062,000£77,407,000
Equity £62,062,000£77,407,000
Average employees 72
Wages £1,476,000£979,000

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin 2.2%-11.4%
Net margin 522.4%1256.8%
Return on capital employed 0.1%-0.2%
Current ratio 5.85x5.08x
Interest cover 1.72x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 102
Reporting scope
Standalone (parent only)
Auditor
Ernst & Young, Chartered Accountants
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The Company generated a net profit of £15,345,000 (2023: net profit £11,969,000), has net assets of £77,407,000 (2023: net assets of £62,062,000) and current assets of the Company exceeded its current liabilities by £64,353,000 (2023: £49,008,000). Trading profits are expected to continue in the foreseeable future. Therefore, after making enquiries, the Directors have a reasonable expectation that the Company will continue in operational existence for a period of twelve months from the date of approval of these financial statements. Accordingly, the Directors continue to adopt the going concern basis of accounting in preparing the annual report and financial statements.”

Group structure

  1. ABBOTT HEALTHCARE PRODUCTS LTD · parent
    1. British Colloids Limited 100% · England and Wales · to hold, for capital growth and income generation, equity shareholdings in other companies within the Group.

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

4 active · 33 resigned

Name Role Appointed Born Nationality
GOGAY, Kevan Secretary 2015-02-13
CAMPBELL, Ross Iain Director 2025-04-25 Apr 1976 British
CLAYTON, Michael Robert Kendall Director 2020-03-23 Apr 1974 British
WENNER, James Russell Director 2025-12-10 Sep 1967 American
Show 33 resigned officers
Name Role Appointed Resigned
BOOTE, Michael George Ernest Secretary 1996-09-30
CHAPMAN, Michael James Secretary 1996-10-01 1998-12-31
DAWES, Melvin John Secretary 1999-01-01 2001-02-23
ABOGADO NOMINEES LIMITED Corporate Secretary 2010-02-15 2015-02-13
SOLVAY UK HOLDING COMPANY LIMITED Corporate Secretary 2001-02-23 2010-02-15
BARRACLOUGH, Richard Alan Director 1996-09-03 1999-09-30
BOOTE, Michael George Ernest Director 1996-09-03
BROECKS, Bert Christian Director 2003-06-16 2006-12-12
BROENS, Daniel Director 2001-03-05 2006-12-12
DAVIES, Alison Elizabeth Director 2023-10-15 2025-12-10
DE LAVENNE DE LA MONTOISE, Bertrand Director 2013-07-01 2014-12-12
DE SLOOVER, Christian, Dr Director 1997-10-01 1999-06-30
DEE, Thomas Joseph Director 2010-02-15 2013-09-30
DUQUENNE, Thierry Amaury Adrien Marie Director 2006-12-12 2008-01-01
ERNST, Jurgen Director 1997-10-01 2005-01-01
FREYMAN, Thomas Craig Director 2010-02-15 2015-12-15
HALL, Gary James Director 2015-10-02 2018-09-27
HARRIS, Neil Director 2018-08-31 2025-04-25
HUDSON, Susan Michelle Director 2016-11-28 2018-08-31
KOZMINA, Natalia Sergeyevna Director 2011-07-20 2013-05-31
KRAMMER, Karen Ann Director 2020-03-01 2022-09-19
MCCOY JR, John Arthur Director 2022-09-19 2023-10-15
MOUNTRICHAS, Georgios Director 2018-09-27 2020-03-23
PETER, John Beverly, Dr Director 2008-01-01
SAKSIDA, Kristian Thomas Dominic Director 1999-09-30 2003-06-30
SMITH, Michael James Director 2015-02-13 2015-10-02
TRAVERSE, Bertrand Director 2007-04-20 2010-02-15
VAN ROYE, Gerard Jean Marie Director 2008-01-01 2010-02-15
WEIDAUER, Thomas Jurgen, Dr Director 2008-01-01 2011-03-15
WEITEKAMPER, Frank Director 2010-02-15 2017-01-05
WESSOLOWSKI, Jurgen Director 1999-07-19 2012-10-30
WITTELAAR, Joseph Director 1999-04-16
YOOR, Brian Director 2015-12-15 2020-02-29

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Abbott Laboratories Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2016-04-06 Active
Abbott Laboratories Inc. Corporate entity Shares 75–100%, voting-rights-75-to-100-percent-as-trust 2016-04-06 Active

Filing timeline

Last 20 of 189 total filings

Date Type Category Description
2025-12-15 AP01 officers Appoint person director company with name date PDF
2025-12-15 TM01 officers Termination director company with name termination date PDF
2025-11-21 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-09-08 AA accounts Accounts with accounts type full
2025-05-01 AP01 officers Appoint person director company with name date PDF
2025-04-30 TM01 officers Termination director company with name termination date PDF
2024-11-20 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-07-22 AA accounts Accounts with accounts type full
2024-04-03 CS01 confirmation-statement Confirmation statement with no updates PDF
2023-10-25 AP01 officers Appoint person director company with name date PDF
2023-10-25 TM01 officers Termination director company with name termination date PDF
2023-08-24 AA accounts Accounts with accounts type full
2023-03-22 CS01 confirmation-statement Confirmation statement with no updates PDF
2022-09-27 AP01 officers Appoint person director company with name date PDF
2022-09-27 TM01 officers Termination director company with name termination date PDF
2022-08-09 AA accounts Accounts with accounts type full
2022-03-24 CS01 confirmation-statement Confirmation statement with no updates PDF
2021-10-07 AA accounts Accounts with accounts type full
2021-03-24 CS01 confirmation-statement Confirmation statement with no updates PDF
2020-10-07 AA accounts Accounts with accounts type full

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
5

last 12 months

Capital events
0

last 24 months

Officers appointed
1

last 12 months

Officers resigned
1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page